Literature DB >> 2860571

Release of dynorphin-like immunoreactivity from rat anterior pituitary gland in vitro.

W Knepel, M Schwaninger.   

Abstract

Rat anterior pituitary quarters were incubated in vitro and the release of dynorphin A1-13-like immunoreactivity (Dyn A1-13-IR) into the incubation medium was studied. An elevation of the potassium concentration of the incubation medium to 40 mmol/l increased the release of Dyn A1-13-IR in a calcium-dependent manner. Addition of luteinizing hormone-releasing hormone (LHRH) stimulated the release of Dyn A1-13-IR in a dose-dependent manner. The LHRH-induced release of Dyn A1-13-IR was almost completely prevented by omission of calcium ions from the incubation medium or by addition of the LHRH-antagonist D-pGlu1,D-Phe2,D-Trp3,6-LHRH. This is the first demonstration that dynorphin-like immunoreactivity can be released from the rat adenohypophysis through calcium-dependent mechanisms by both high potassium concentration and receptor-mediated stimulation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2860571     DOI: 10.1007/bf00695198

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  14 in total

1.  Relation of endogenous opioid peptides and morphine to neuroendocrine functions.

Authors:  J Meites; J F Bruni; D A Van Vugt; A F Smith
Journal:  Life Sci       Date:  1979-04-09       Impact factor: 5.037

2.  [D-pGlu1,D-Phe2,D-Trp3,6]-LRF. A potent luteinizing hormone releasing factor antagonist in vitro and inhibitor of ovulation in the rat.

Authors:  J E Rivier; W W Vale
Journal:  Life Sci       Date:  1978-08-28       Impact factor: 5.037

3.  Response of the perifused anterior pituitaries of rats to synthetic gonadotrophin releasing hormone: a comparison with hypothalamic extract and demonstration of a role for potassium in the release of luteinizing hormone and follicle-stimulating hormone.

Authors:  L W Kao; G L Gunsalus; G H Williams; J Weisz
Journal:  Endocrinology       Date:  1977-11       Impact factor: 4.736

4.  Relative contents and concomitant release of prodynorphin/neoendorphin-derived peptides in rat hippocampus.

Authors:  C Chavkin; C Bakhit; E Weber; F E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

5.  Concomitant neonatal development and in vitro release of dynorphin and alpha-neo-endorphin.

Authors:  B R Seizinger; D Maysinger; V Höllt; C Grimm; A Herz
Journal:  Life Sci       Date:  1982 Oct 18-25       Impact factor: 5.037

6.  Release of dynorphin-like immunoreactivity of rat neurohypophysis in comparison to vasopressin after various stimuli in vitro and in vivo.

Authors:  H Anhut; W Knepel
Journal:  Neurosci Lett       Date:  1982-08-16       Impact factor: 3.046

7.  Dynorphin and dynorphin are ligands for the kappa-subtype of opiate receptor.

Authors:  A D Corbett; S J Paterson; A T McKnight; J Magnan; H W Kosterlitz
Journal:  Nature       Date:  1982-09-02       Impact factor: 49.962

8.  Dynorphin is a specific endogenous ligand of the kappa opioid receptor.

Authors:  C Chavkin; I F James; A Goldstein
Journal:  Science       Date:  1982-01-22       Impact factor: 47.728

9.  Immunoreactive dynorphin in pituitary and brain.

Authors:  A Goldstein; V E Ghazarossian
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

10.  In vitro adrenocorticotropin/beta-endorphin-releasing activity of vasopressin analogs is related neither to pressor nor to antidiuretic activity.

Authors:  W Knepel; L Homolka; M Vlaskovska; D Nutto
Journal:  Endocrinology       Date:  1984-05       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.